手术切除与化疗相结合已经被证明可以显著提高胰腺导管腺癌（PDAC）患者的生存率。然而，超过50%的病例被诊断出有转移，因此这种治疗选择只适用于部分患者。转移的多方面过程仍然不完全了解，但最近的数据表明转录和表观遗传可塑性起着重要作用。干预表观遗传重编程可能控制对转移性进展和治疗抵抗性负责的适应性过程，从而增强治疗反应并防止复发。本综述将重点讨论组蛋白修饰酶在胰腺癌中的相关性，特别是它们对转移级联反应的影响。此外，本文还将简要介绍目前表观遗传治疗的临床发展的最新进展。© 2023年。作者

Surgical resection, when combined with chemotherapy, has been shown to significantly improve the survival rate of patients with pancreatic ductal adenocarcinoma (PDAC). However, this treatment option is only feasible for a fraction of patients, as more than 50% of cases are diagnosed with metastasis. The multifaceted process of metastasis is still not fully understood, but recent data suggest that transcriptional and epigenetic plasticity play significant roles. Interfering with epigenetic reprogramming can potentially control the adaptive processes responsible for metastatic progression and therapy resistance, thereby enhancing treatment responses and preventing recurrence. This review will focus on the relevance of histone-modifying enzymes in pancreatic cancer, specifically on their impact on the metastatic cascade. Additionally, it will also provide a brief update on the current clinical developments in epigenetic therapies.© 2023. The Author(s).